

Prematurely ended - Statement

EudraCT Number:	2021-002818-13
Full title of the study:	A Randomized, Double-blind, Placebo-controlled, Phase 2, 12-Week Treatment Study with a 10-Week Follow-up Period to Assess the Efficacy and Safety of Benralizumab (anti-IL5R α) in Adult Patients with Chronic Prurigo
Sponsor-Code:	DEALSZ-2021-001
Short title:	BICPIC
Sponsor:	Charité – Universitätsmedizin Berlin; Institute of Allergology; Hindenburgdamm 30, 12203 Berlin
Contact name:	Dr. Benjamin Grimmer bicpic-ifa@charite.de
Product:	Fasenra (Benralizumab)
Date of early termination:	2023/10/19
Statement:	The trial was terminated early by the funder.